Abstract
The objective of this study is to use quantitative analysis to reveal the factors determining innovation in major domestic pharmaceutical companies. We conducted a questionnaire survey for 43 companies. This research clarified; 1) Both Companies possessing biopharmaceutical products and companies with an annual product turnover equal to or surpassing 20 billion yen are pursuing activities to protect their proprietary position such as securing patents and, as a result, gaining profits from these activities. 2) Companies possessing biopharmaceutical products have technological opportunities but they may not have achieved annual product turnover equal to or surpassing 20 billion yen. 3) Major domestic pharmaceutical companies are heavily influenced by the universities to keep possessing biopharmaceutical products or products whose annual sales exceeded 20 billion yen, and there is a possibility that the open innovation model is compatible.
